scholarly journals Breast Cancer Type 1 Susceptibility Protein

2020 ◽  
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Cancer Type ◽  
Breast Cancer Type

scholarly journals Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review

2019 ◽  
Vol 73 (4) ◽  
pp. 191-196 ◽  
Author(s):  
Lorena Alves Teixeira ◽  
Francisco Jose Candido dos Reis
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Ovarian Cancer ◽  
Cancer Type ◽  
Loss Of Function ◽  
Brca1 And Brca2 ◽  
Brca1 Protein ◽  
Current Usage ◽  
Breast Cancer Type

BackgroundLoss of function in either breast cancer type 1 susceptibility protein (BRCA1) or breast cancer type 2 susceptibility protein (BRCA2) is a major risk factor for epithelial ovarian cancer (EOC) development. BRCA1 or BRCA2 deficiencies are associated with short-term prognosis and might have importance for the treatment of women with the disease. However, the screening of all possible mechanisms of dysfunction is expensive, time-consuming and difficult to apply in clinical practice. On the other hand, immunohistochemistry (IHC) is a simple and reliable method to access the expression of several proteins in tumour tissues.Materials and methodsThis systematic review aims to evaluate the current usage of IHC to detect BRCA1 and BRCA2 deficiencies in EOC. We searched and evaluated all primary literature on the use of IHC for evaluating BRCA1 and BRCA2 proteins expression in EOC. The main concepts for the search were: ovarian neoplasms, IHC, BRCA1 and BRCA2.ResultsForty-four studies from 925 unique titles were included. A total of 4206 tumour samples were evaluated for BRCA1 and 1041 for BRCA2 expression. Twelve BRCA1 primary antibodies were used in 41 studies, and the most common was the MS110 clone (75.6%). Seven BRCA2 primary antibodies were used in ten studies. Using the cut-off of 10%, 47.0% of EOCs are associated with loss of BRCA1 and 34.5% with the loss of BRCA2 expression.ConclusionIHC was effective to detect loss of BRCA1 protein expression in EOC; however, data on BRCA2 expression were heterogeneous and difficult to interpret.

scholarly journals How latent viruses cause breast cancer: An explanation based on the microcompetition model

2018 ◽  
Author(s):  
Hanan Polansky ◽  
Hava Schwab
Keyword(s):  
Breast Cancer ◽  
Brca1 Gene ◽  
Breast Tumors ◽  
Cancer Type ◽  
Brca1 Expression ◽  
Breast Cancer Type

Most breast cancer cases show a decrease in the concentration of the breast cancer type 1 susceptibility protein (BRCA1). However, only a small portion of these cases have a mutated BRCA1 gene. Although many attempts have been made to identify the reason for the decrease in BRCA1 expression in sporadic, non-heritable breast cancer cases, the cause is still unknown. In this review, we use the Microcompetition Model to explain how certain latent viruses, which are frequently detected in breast cancer tumors, can decrease the expression of the BRCA1 gene and cause the development of breast tumors.

scholarly journals Extent of breast cancer type 1 promoter methylation correlates with clinicopathological features in breast cancers

2018 ◽  
Vol 14 (9) ◽  
pp. 354
Author(s):  
Chang-Qing Wang ◽  
Mei-Yang Sun ◽  
Xin-Zhong Chang ◽  
Gui-Ying Xu ◽  
Yi Dong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Promoter Methylation ◽  
Clinicopathological Features ◽  
Cancer Type ◽  
Breast Cancers ◽  
Breast Cancer Type
Sign in / Sign up

Export Citation Format

Share Document